Mehmet Akyüz

Evaluation of germ-cell neoplasia in situ entity in testicular tumors

OBJECTIVE Germ-cell neoplasia in situ (GCNIS) is accepted as the precursor of the testicular tumors. The aim in our study is to compare the lymphadenopathy and metastasis parameters in patients diagnosed with testicular tumor with or without GCNIS based on pathological evaluation. MATERIAL AND METHODS Data from 108 patients who underwent orchiectomy for testicular tumor between January 2007 and December 2014 in our clinic were retrospectively analyzed and included in the study. Patients were divided into two groups based on the pathology reports as GCNIS or not. Groups were compared regarding lymphadenopathy, metastasis, tumor marker levels, tumor size, lymphovascular invasion, rete testis invasion. Mann-Whitney U test was used for statistical evaluation. RESULTS Mean age of the patients included in the study were calculated as 34.6±9.3 years. Eighty-five (78.7%) patients had GCNIS, while 23 (21.3%) of them had not. In terms of metastasis, lymphadenopathy, marker levels, tumor size, lymphovascular invasion and rete testis invasion, no statistical significant difference were observed between two groups (p>0.05). CONCLUSION In our study, no statistical significant difference was observed on the prognostic factors concerning the GCNIS entity, which is reported frequently in testicular tumor pathologies. For presently these findings show us that GCNIS cannot be used as a prognostic factor.

Changing the Stage, Grade and Histological Subtypes of Renal Cell Carcinomas during 10 Years Period

Renal cell carcinomas (RCCs) account 80-85% of all primary renal neoplasms and originate from the renal cortex. The patients who underwent radical or partial nephrectomy for renal tumour in our unit between January 2005 and 2015 were evaluated retrospectively. The patients were divided into two groups; group 1 includes patients who were treated between January 2005 and December 2009, group 2 those from January 2010 to 2015. There were 103 patients in group 1. The patients were between 21 and 89 years with mean age of 61.46 year. Renal cell carcinomas account 83.4% of the patients, benign renal tumours were 8.7% and transitional cell carcinomas were 7.7% of the patients in group 1. A total of 32.5% RCCs were classified as pT1a, 24.4% as pT1b, 15.1% as pT2a, 11.6% as pT2b, 15.1% as pT3a and 1.1% as pT4. There were 202 patients in group 2 and the patients were between 27 and 81 years with mean age of 58.5 year. Renal cell carcinomas comprised the main bulk of the tumours with 182 nephrectomy specimens. According to the pathological classification of RCCs, 51 specimens were found as pT1a, 54 were pT1b, 13 were pT2a, 14 were pT2b, 48 were pT3a and 2 were pT4. Although, the incidence of small renal masses has been increasing with widespread use of imaging techniques and recent advancements, the proportion of high grade and advanced stage renal tumours increased during the study period.

The use of primary and secondary doxazosin XL (8 mg) in the treatment of benign prostate hyperplasia: Is there a new approach in the event of alpha-blocker failure?

OBJECTIVE Lower urinary tract symptoms (LUTS), which are related to benign prostate hyperplasia (BPH), are the most commonly encountered diseases in urological practice. In our study, we compared responses to (doxazosin mesylate extended release tablets) treatment. MATERIAL AND METHODS In our study, we included one hundred patients with LUTS who did not receive any medical treatment, and one hundred patients with LUTS who did not respond to alpha-blocker drugs other than doxazosin XL (8 mg). The inclusion criteria for the study were as follows: international prostate symptom score (IPSS)>7, prostate volume >20 cc, Q-max <15 mL/sn, lack of any previous pelvic or prostatic surgery, and /or urethral catheterization. RESULTS The mean age of the patients was 62.2±7.9 years. No statistically significant differences were detected between the groups with respect to age, prostate volume, and total prostate-specific antigen (PSA) levels. The duration of the follow-up period was calculated as 3-26 (mean 11) months. Significant differences were detected in post-voiding residual urine, IPSS, quality of life and Qmax between pre- and post-treatment values. Similar decreases in the IPSS scores, and increases in Qmax values were detected in both groups. CONCLUSION Doxazosin XL (8 mg) treatment was found to be efficient and reliable in primary patients and in patients with severe LUTS who did not respond to medical treatment. Trial of doxazosin XL (8 mg) therapy, before surgery in patients who respond inadequately to other alpha-blocker drugs is a rational approach.

TRANSREKTAL ULTRASONOGRAFİ EŞLİĞİNDE ALINAN PROSTAT BİYOPSİLERİNDE GLEASON 5 PATERNİ

Objectives: Prostate cancer is the most seen cancer in developed country and second reason of cancer related died in this population. We evalutaed the survival of the patients who had Gleason 5 patern on transrectal ultrasoun guided prostate biopsy. Material and Methods: The patients who had Gleason 5 patern underwent transrectal ultrasound guided prostate biopsy between 2005-2010 years included in the study. Seventy-six patients who were followed in our policilinic or died were recorded. Age at diagnosis, time of following, treatments, scores of Gleason, level of PSA’s at diagnosis and last were recorded. Results: Mean age of the patients, PSA levels, prostate volumes and following times are 69.4±8.6, 245.9±517.3 ng/ml, 57.2±30.6 cc and 38.8±12.3 months. Gleason 10,9,8 scores were detected in 6 (%7.9),68(%89.5) and 2(%2.6) patients.26 patients were treated surgical castration,44 patients were treated medical castration. Both radical prostatectomy and medical castration were performed on 6 patients. Twenty-two patients were treated with transurethral resection of prostate because of lower urinary tract symptoms. Eighteen patients died on following days mean time at 21.3±9.8 months. Conclusion: High grade prostate cancer is one of the major problems in daily practice. These patients progress to advanced stage because of the high Gleason score. High grade prostate cancer is one of the more common causes of cancer related death despite all treatments methods.